455 related articles for article (PubMed ID: 28775119)
21. B-cell receptor inhibitors in chronic lymphocytic leukemia.
Flinn IW
Clin Adv Hematol Oncol; 2011 Aug; 9(8):605-6. PubMed ID: 22236988
[No Abstract] [Full Text] [Related]
22. Idelalisib- a PI3Kδ targeting agent for B-cell malignancies.
Hewett YG; Uprety D; Shah BK
J Oncol Pharm Pract; 2016 Apr; 22(2):284-8. PubMed ID: 25712626
[TBL] [Abstract][Full Text] [Related]
23. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.
Grommes C; Pastore A; Palaskas N; Tang SS; Campos C; Schartz D; Codega P; Nichol D; Clark O; Hsieh WY; Rohle D; Rosenblum M; Viale A; Tabar VS; Brennan CW; Gavrilovic IT; Kaley TJ; Nolan CP; Omuro A; Pentsova E; Thomas AA; Tsyvkin E; Noy A; Palomba ML; Hamlin P; Sauter CS; Moskowitz CH; Wolfe J; Dogan A; Won M; Glass J; Peak S; Lallana EC; Hatzoglou V; Reiner AS; Gutin PH; Huse JT; Panageas KS; Graeber TG; Schultz N; DeAngelis LM; Mellinghoff IK
Cancer Discov; 2017 Sep; 7(9):1018-1029. PubMed ID: 28619981
[TBL] [Abstract][Full Text] [Related]
24. Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
McDermott J; Jimeno A
Drugs Today (Barc); 2014 Apr; 50(4):291-300. PubMed ID: 24918646
[TBL] [Abstract][Full Text] [Related]
25. Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature.
Shaikh H; Khattab A; Faisal MS; Chilkulwar A; Albrethsen M; Sadashiv S; Fazal S
J Oncol Pharm Pract; 2019 Jul; 25(5):1265-1270. PubMed ID: 30045682
[TBL] [Abstract][Full Text] [Related]
26. Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Coutré SE; Furman RR; Flinn IW; Burger JA; Blum K; Sharman J; Jones J; Wierda W; Zhao W; Heerema NA; Johnson AJ; Tran A; Zhou C; Bilotti E; James DF; Byrd JC; O'Brien S
Clin Cancer Res; 2017 Mar; 23(5):1149-1155. PubMed ID: 28073846
[No Abstract] [Full Text] [Related]
27. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.
Mato AR; Nabhan C; Barr PM; Ujjani CS; Hill BT; Lamanna N; Skarbnik AP; Howlett C; Pu JJ; Sehgal AR; Strelec LE; Vandegrift A; Fitzpatrick DM; Zent CS; Feldman T; Goy A; Claxton DF; Bachow SH; Kaur G; Svoboda J; Nasta SD; Porter D; Landsburg DJ; Schuster SJ; Cheson BD; Kiselev P; Evens AM
Blood; 2016 Nov; 128(18):2199-2205. PubMed ID: 27601462
[TBL] [Abstract][Full Text] [Related]
28. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.
Noy A; de Vos S; Thieblemont C; Martin P; Flowers CR; Morschhauser F; Collins GP; Ma S; Coleman M; Peles S; Smith S; Barrientos JC; Smith A; Munneke B; Dimery I; Beaupre DM; Chen R
Blood; 2017 Apr; 129(16):2224-2232. PubMed ID: 28167659
[TBL] [Abstract][Full Text] [Related]
29. A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.
Lee CS; Rattu MA; Kim SS
J Oncol Pharm Pract; 2016 Feb; 22(1):92-104. PubMed ID: 25425007
[TBL] [Abstract][Full Text] [Related]
30. Ibrutinib and indolent B-cell lymphomas.
Akinleye A; Furqan M; Adekunle O
Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):253-60. PubMed ID: 24445187
[TBL] [Abstract][Full Text] [Related]
31. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.
Lampson BL; Brown JR
Expert Opin Investig Drugs; 2017 Nov; 26(11):1267-1279. PubMed ID: 28945111
[TBL] [Abstract][Full Text] [Related]
32. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
Davids MS; Kim HT; Nicotra A; Savell A; Francoeur K; Hellman JM; Bazemore J; Miskin HP; Sportelli P; Stampleman L; Maegawa R; Rueter J; Boruchov AM; Arnason JE; Jacobson CA; Jacobsen ED; Fisher DC; Brown JR;
Lancet Haematol; 2019 Jan; 6(1):e38-e47. PubMed ID: 30558987
[TBL] [Abstract][Full Text] [Related]
33. Idelalisib for treatment of B-cell malignancies.
Do B; Mace M; Rexwinkle A
Am J Health Syst Pharm; 2016 Apr; 73(8):547-55. PubMed ID: 26933132
[TBL] [Abstract][Full Text] [Related]
34. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.
Mato AR; Hill BT; Lamanna N; Barr PM; Ujjani CS; Brander DM; Howlett C; Skarbnik AP; Cheson BD; Zent CS; Pu JJ; Kiselev P; Foon K; Lenhart J; Henick Bachow S; Winter AM; Cruz AL; Claxton DF; Goy A; Daniel C; Isaac K; Kennard KH; Timlin C; Fanning M; Gashonia L; Yacur M; Svoboda J; Schuster SJ; Nabhan C
Ann Oncol; 2017 May; 28(5):1050-1056. PubMed ID: 28453705
[TBL] [Abstract][Full Text] [Related]
35. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
Till KJ; Pettitt AR; Slupsky JR
J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
[TBL] [Abstract][Full Text] [Related]
36. PI3K-δ inhibitor produces long-lasting responses.
Cancer Discov; 2013 Jul; 3(7):OF11. PubMed ID: 23847354
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax.
Waldron M; Winter A; Hill BT
Clin Pharmacokinet; 2017 Nov; 56(11):1255-1266. PubMed ID: 28343293
[TBL] [Abstract][Full Text] [Related]
38. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
[TBL] [Abstract][Full Text] [Related]
39. Duvelisib: a new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia.
Frustaci AM; Tedeschi A; Deodato M; Zamprogna G; Cairoli R; Montillo M
Future Oncol; 2019 Jul; 15(19):2227-2239. PubMed ID: 31137964
[TBL] [Abstract][Full Text] [Related]
40. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
Thompson PA; Burger JA
Expert Opin Investig Drugs; 2018 Jan; 27(1):31-42. PubMed ID: 29125406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
